Trials / Completed
CompletedNCT00463151
An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the safety and efficacy of rebamipide by once daily intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with active ulcerative colitis, who are being treated with oral aminosalicylic acid (ASA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rebamipide | 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2007-04-20
- Last updated
- 2021-07-20
- Results posted
- 2021-07-20
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00463151. Inclusion in this directory is not an endorsement.